Akebia Therapeutics Inc — Quarterly Cash Flow (NASDAQ:AKBA) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 220.67 M310.19 M345.6 M364.15 M376.56 M362.52 M Total liabilities 269.86 M285.6 M316.37 M322.56 M343.95 M335.14 M Total equity -49.19 M24.58 M29.22 M41.59 M32.61 M27.38 M Total liabilities & shareholders' equities 220.67 M310.19 M345.6 M364.15 M376.56 M362.52 M Total debt 38.69 M46.51 M47.06 M47.64 M48.25 M48.89 M Net debt 38.69 M46.51 M-90.25 M-118.8 M-136.59 M-113.75 M

News

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates

Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Are Options Traders Betting on a Big Move in Akebia Therapeutics Stock?

New Strong Sell Stocks for April 28th

Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day - Slideshow (NASDAQ:AKBA) 2026-04-04

Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript

Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript

Akebia at Leerink Conference: Strategic Focus on Vafseo and Pipeline

3 Best Stocks to Buy Today with 125%+ Upside, 2/27/2026, According to Top Analysts - TipRanks.com

Ardelyx (ARDX) Reports Break-Even Earnings for Q4